President Trump announced that generic drugs imported into the United States will keep a zero percent tariff for two years starting August 1, 2026, but after that grace period the tariff jumps to 100 percent for a year, then rises again to 200 percent. The goal, he said, is to push generic drug makers to build factories inside the US instead of relying on imports, with the tariff acting as a penalty for companies that don't relocate production in time. Branded and patented drugs are not affected, Trump said, since that separate tariff policy has already worked well. He added that pharmaceutical plants are being built across the country at a scale not seen before. Generic drugs make up the vast majority of prescriptions filled in the US, most made overseas in India, China and elsewhere at low cost, so a multiyear runway before the tariff bites gives companies time to plan, but the eventual 100 and 200 percent rates would make continued importing far more expensive than building domestically. The delayed start also means markets have time to price in the shift gradually rather than react to an immediate shock, though it sets a clear multiyear deadline that reshapes how drugmakers plan capacity.
Why it matters · Generic drugs are cheap precisely because they're made overseas, so a scheduled tariff wall reshapes where pharma capex flows over the next several years and could eventually affect drug supply and pricing in the US.
Worth asking · A two-year grace period before the tariff bites: enough time for generic drugmakers to reshore production, or just a delay before US drug costs rise?